Arpeggio Biosciences

Arpeggio Biosciences

A a biotechnology company developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Arpeggio Biosciences is a biotechnology company headquartered in Boulder, Colorado that was founded in 2017 by Robin Dowell and Joey Azofeifa. Arpeggio Biosciences headquarters is located in the BioFrontiers Institute in the University of Boulder Colorado. The company is developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Drug screening

The companies drug screening platform can be used by scientists performing research related to drug discovery and the mechanisms of action underlying the effectiveness of drugs. The drug screening platform provides time series profiling of drug compounds using RNA-profiling technology to gain insight into how thousands of genes are interacting within the human body. The company then uses machine learning algorithms to analyze the time series profile to discover causal signalling networks, which can give researchers insight into the underlying mechanisms of action for their drugs, and help them predict how a certain drug will affect a patient.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Arpeggio Biosciences, Inc. funding round, September 2019
3,000,000
September 2019
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dan Weaver

CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.